Clinical efficacy of etoposide soft capsules oral monotherapy in second-line treatment of elderly patients with recurrent small cell lung cancer / 中国生化药物杂志

ABSTRACT

Objective To observe the clinical efficacy and safety of etoposide capsule (VP16) in the treatment of recurrent small cell lung cancer. Methods Retrospective analysis 39 patients,aged≥65, with relapsed small cell lung cancer, who were at least three months after the end of the first-line treatment since January 2012 to January 2014 in Tianjin fifth central hospital.Etoposide was administered by daily oral at 100 mg/day for seven consecutive days and withdraw for 14 days,21 days as a therapeutic cycle,repeat treatment until disease progression or intolerable side effects occur, analyze the progression-free survival and overall survival.Observe the clinical benefit rate,the overall response rate and safety.Results The clinical benefit rate (DCR) and overall response rate (ORR) after the treatment were 61.5% and 30.77%.The progression-free survival (PFS) was 2.8 months, and the overall survival (OS) was 7.3 months.Neutropenia is the most common toxicities, and grade Ⅲ or Ⅳ occurred in 7.7% of the patients.No grade Ⅲ or Ⅳ thrombocytopenia, or grade Ⅲ or Ⅳ non-hematologic toxicity was occured.Conclusion Etoposide oral capsules monotherapy may be considered as one of the safe and effective choice of the second-line treatment of elderly patients with relapsed small cell lung cancer.